During the last session, Plus Therapeutics Inc (NASDAQ:PSTV)’s traded shares were 0.46 million, with the beta value of the company hitting 0.70. At the end of the trading day, the stock’s price was $1.18, reflecting an intraday loss of -1.67% or -$0.02. The 52-week high for the PSTV share is $2.67, that puts it down -126.27 from that peak though still a striking 3.39% gain since the share price plummeted to a 52-week low of $1.14. The company’s market capitalization is $6.96M, and the average intraday trading volume over the past 10 days was 71780.0 shares, and the average trade volume was 72.53K shares over the past three months.
Plus Therapeutics Inc (NASDAQ:PSTV) trade information
Plus Therapeutics Inc (PSTV) registered a -1.67% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.67% in intraday trading to $1.18, hitting a weekly high. The stock’s 5-day price performance is 0.85%, and it has moved by -12.60% in 30 days. Based on these gigs, the overall price performance for the year is -34.44%. The short interest in Plus Therapeutics Inc (NASDAQ:PSTV) is 52339.0 shares and it means that shorts have 0.98 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Plus Therapeutics Inc (PSTV) estimates and forecasts
Statistics show that Plus Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Plus Therapeutics Inc (PSTV) shares have gone down -44.86% during the last six months, with a year-to-date growth rate more than the industry average at 52.83% against 16.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 22.86% this quarter and then jump 36.44% in the quarter after that. In the rating firms’ projections, revenue will increase 8.85% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.19M as predicted by 4 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 1.73M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.31M and 1.68M respectively. In this case, analysts expect current quarter sales to shrink by -9.18% and then jump by 3.36% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 68.20%. While earnings are projected to return 55.60% in 2024.
PSTV Dividends
Plus Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Plus Therapeutics Inc (NASDAQ:PSTV)’s Major holders
Plus Therapeutics Inc insiders own 2.34% of total outstanding shares while institutional holders control 11.39%, with the float percentage being 11.66%.
Also, the Mutual Funds coming in first place with the largest holdings of Plus Therapeutics Inc (PSTV) shares are Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Fidelity Extended Market Index Fund owns about 36.27 shares. This amounts to just over 0.62 percent of the company’s overall shares, with a $42792.0 market value. The same data shows that the other fund manager holds slightly less at 32.54, or about 0.55% of the stock, which is worth about $38398.0.
